Skip to content
World Health Systems Facts

Spain: Pharmaceuticals

Spanish Health System Overview
Health System Rankings
Health System Outcomes
Health System Coverage
Costs for Consumers
Health System Expenditures
Spanish COVID-19 Policy

Health System Financing
Health System Personnel
Health System Physical Resources and Utilization
Long-Term Services & Supports
Health Information and Communications Technologies
Medical Training
Pharmaceuticals

Political System
Economic System
Population Demographics
People With Disabilities
Aging
Social Determinants & Health Equity
Health System History
Health System Challenges


Expenditure On Retail Pharmaceuticals Per Capita, 2017 (USD$ PPP)
Prescribed Medicines: $375
Over-The-Counter Medicines: $200
Medical Non-Durable: $23
Total: $598

Source: OECD (2019), Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/4dd50c09-en.


Expenditure On Retail Pharmaceuticals By Type Of Financing, 2017 (%)
Government/Compulsory Plans: 58%
Voluntary Health Insurance Plans: 0%
Out-Of-Pocket: 42%
Other: 0%

Source: OECD (2019), Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/4dd50c09-en.


“In terms of the overall budgetary impact of pharmaceuticals, and subsequent implications for allocative efficiency, in 2016 the number of pharmaceutical prescriptions (not including hospital prescriptions) increased by 2.2%, reaching an overall expenditure of €9.9 billion, €377.8 million more than in 2015. This growth was very much due to an increase in the volume of existing drugs (accounting for nearly 4% of growth) and to a lesser extent to new market drugs (up to 2.5%). These figures maintain the trend that started in 2013 when the effect of the cost-containment measures, in particular RDL 16/2012 in which new co-payment mechanisms were issued, faded away.

“In spite of strong cost-containment policies, the variation across Spanish ACs [Autonomous Communities] is remarkable. In fact, the growth in prescriptions differed as much as 11.5 times between the region of Valencia with the largest increase (5.3%) and Catalonia, which experienced only 0.46% growth. In terms of expenditure, the region of Valencia showed the highest increase (6.7%) and Galicia the smallest (1.6%). Finally, the average reimbursement price (€10.99) was observed to vary from €12.87 in the Basque Country to €10.10 in Andalusia (MSSSI, 2017p).

“In comparative terms, in 2014, overall per capita expenditure was €391, slightly lower than the EU27 average (€402); out of them, 68.8% (€269) was expenditure due to drugs ‘under prescription’. As compared with other health services, where public contribution is 76% of total health expenditure, public share on pharmaceuticals spending was 61%; in EU27, the average was 64% compared with 83% of public contribution to other health services.”

Source: Bernal-Delgado E, García-Armesto S, Oliva J, Sánchez Martínez FI, Repullo JR, PeñaLongobardo LM, Ridao-López M, Hernández-Quevedo C. Spain: Health system review. Health Systems in Transition, 2018;20(2):1–179.


“The Spanish pharmaceutical sector is one of the most regulated sectors of the Spanish economy. In addition to the centralized approval mechanism provided by the European Medicines Agency, the Spanish Agency for Medicines has to approve the effective commercialization of any drug, as well as the regulation for drugs pricing and public reimbursement. Once commercialization is approved, companies might seek public reimbursement. This decision will be made by the Inter-ministerial Commission on Prices of Medicines, an administrative advisory body of the Ministry of Health, according to a number of criteria:

“ƒ severity, duration and consequences of the disease for which the drug is indicated;

“ƒ specific needs of certain groups;

“ƒ therapeutic and social value and incremental clinical benefit in terms of cost-effectiveness;

“ƒ budgetary impact;

“ƒ existence of drugs or other therapeutic alternatives at a lower price or lower cost of treatment; and,

“ƒ the degree of innovation of the drug under evaluation.”

Source: Bernal-Delgado E, García-Armesto S, Oliva J, Sánchez Martínez FI, Repullo JR, PeñaLongobardo LM, Ridao-López M, Hernández-Quevedo C. Spain: Health system review. Health Systems in Transition, 2018;20(2):1–179.


“The regulation scheme issued in the Act for Guarantees and Rational Use of Pharmaceuticals and Health Products (Law 29/2006) has not significantly changed in terms of actors and responsibilities (see table 6.9 in García-Armesto et al., 2010). The new regulation issued since 2010 by the central government, has aimed at deepening the regulation issued in the aforementioned law, in a new context of fiscal revenues reduction and growing public debt. Thus,

“ƒ RDL 4/2010 ruled among other elements, the reduction of drug prices in both, drugs already under the reference pricing scheme and those not included yet;

“ƒ RDL 9/2011, among other measures, deepened the reference pricing policy guaranteeing homogeneity across the country, prompted generic prescription through the prohibition of brand-name prescription, and created the Committee on the Cost-Effectiveness of Pharmaceuticals and Health Products, who will report on the price policies developed by the Inter-ministerial Commission on Drugs Pricing;

“ƒ RD 177/2014, developed in the context of RDL 16/2012, that deepened in the regulation of reference prices and groups of homogeneous drugs, also aimed at regulating the information system required for drugs pricing and ACs [Autonomous Communities] financing; and

“ƒ Law 10/2013, modifying technical aspects of Law 29/2006; among the measures the text emphasized the need for the ACs to avoid policies that could lead to differences in pharmaceutical benefits and prices, distorting the in-country ‘single market’ principle and increasing inequalities.”

Source: Bernal-Delgado E, García-Armesto S, Oliva J, Sánchez Martínez FI, Repullo JR, PeñaLongobardo LM, Ridao-López M, Hernández-Quevedo C. Spain: Health system review. Health Systems in Transition, 2018;20(2):1–179.


“With regard to the distribution of medicines (irrespective of liability for SNS reimbursement), the system is organized around 52 wholesalers, chiefly made up of cooperatives of pharmacists. In 2015, six out of the 52 companies held a 75.5% share of the distribution market in Spain (FEDIFAR, 2016), comprising 21 937 pharmacy retailers (independent authorized agents that enjoy protective regulation that limits competition at the level of distribution) (Official General Council of Professional Colleges of Pharmacists, 2015). This regulation restricts to pharmacists the dispensation of prescription drugs, includes rules to prevent geographic concentration of pharmacies, regulates opening hours and, especially, the need for a 5-year university degree – not only to dispense, but also to own a pharmacy – plus compulsory enrolment in the College of Pharmacists. The authorization to open a pharmacy entails an automatic agreement with the regional Health Authorities for the dispensation of medicines prescribed in the SNS. In the case of drugs eligible for public reimbursement, the reimbursement of retail pharmacists and wholesalers relies on fixed and price-proportional mark-ups of the consumer price before tax.”

Source: Bernal-Delgado E, García-Armesto S, Oliva J, Sánchez Martínez FI, Repullo JR, PeñaLongobardo LM, Ridao-López M, Hernández-Quevedo C. Spain: Health system review. Health Systems in Transition, 2018;20(2):1–179.


“Pharmaceutical care, as part of the SNS common benefits package, covers all those medicines and health products approved, registered and eligible for reimbursement as well as actions aiming to ensure that patients receive medicines as required, at the correct dosage, for the right amount of time and at the lowest possible cost to them and to the community. The package does not include cosmetic formulae, dietary products, mineral water, elixirs, toothpaste and other health products, over-the-counter medicines, homeopathic remedies, or any item or accessory advertised targeting the general population. Pharmaceutical care is provided by: (a) doctors, as prescribers and overall supervisors of treatment; (b) nurses, particularly in primary care, in their role of supervisors of adherence and side-effects: and (c) pharmacists, as dispensers and health community agents, supervising treatment adherence and early detection of side-effects.

Source: Bernal-Delgado E, García-Armesto S, Oliva J, Sánchez Martínez FI, Repullo JR, PeñaLongobardo LM, Ridao-López M, Hernández-Quevedo C. Spain: Health system review. Health Systems in Transition, 2018;20(2):1–179.


Health Systems Facts is a project of the Real Reporting Foundation. We provide reliable statistics and other data from authoritative sources regarding health systems in the US and several other nations.


Page last updated May 16, 2021 by Doug McVay, Editor.

  • Home
  • About Health Systems Facts
    • Contact Us
    • Join Our Email List
  • Breaking News & Opinion
  • Upcoming Events
  • Seventeen National Health Systems
    • Austria
    • Canada
    • Costa Rica
    • Czech Republic
    • Denmark
    • France
    • Germany
    • Hungary
    • Italy
    • Japan
    • Netherlands
    • South Korea
    • Spain
    • Sweden
    • Switzerland
    • United Kingdom
    • United States
  • Comparing National Health Systems
    • Healthcare Access and Quality Index
    • Sustainable Development Goals Health Index
    • Mirror Mirror 2021
    • World Health Report 2000
    • International Health Systems In Perspective
    • Lessons for US Health Reform
  • Aging
  • Health System Outcomes
  • Healthcare Spending
  • Healthcare Workers
    • Health System Personnel
    • Health Workforce Training
  • Information and Communications Technologies
  • Long-Term Services and Supports
  • People With Disabilities
  • Pharmaceutical Pricing and Regulation
  • Social Determinants & Health Equity
  • Wasteful Spending
  • Various US Health System Proposals
    • Affordable Care Act
    • All Payer
    • Public Option
    • Single Payer / “Medicare For All”
    • Universal Health Coverage
  • Recommended Resources
  • Privacy Policy
    • Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter

© 2019-2022 Real Reporting Foundation | Theme by WordPress Theme Detector

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
_GRECAPTCHA5 months 27 daysThis cookie is set by Google. In addition to certain standard Google cookies, reCAPTCHA sets a necessary cookie (_GRECAPTCHA) when executed for the purpose of providing its risk analysis.
cookielawinfo-checkbox-advertisement1 yearThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-71314304-21 minuteThis is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.
_gcl_au3 monthsThis cookie is used by Google Analytics to understand user interaction with the website.
_gid1 dayThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
IDE1 year 24 daysUsed by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
test_cookie15 minutesThis cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
Powered by CookieYes Logo